Cambridge Enterprise

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatments. This approach has the potential to provide effective and safe therapies for neurological, inflammatory, and oncological conditions.

Illumion is a technology company specializing in energy storage solutions. It develops and manufactures a lab-based, real-time measurement device that provides detailed insights into energy storage processes at sub-micrometer scales. This device enables researchers to visualize and understand energy storage processes in real-time, optimize material usage, and identify performance limitations at the microscopic level, thereby accelerating battery development and enhancing energy storage efficiency and performance.

52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

AllFocal Optics revolutionizes display technology through groundbreaking nanophotonic solutions.

Upfront Diagnostics specializes in the development of innovative blood biomarkers aimed at improving the diagnosis of stroke patients, particularly those suffering from large vessel occlusions. By facilitating rapid and accurate identification of this stroke subtype, the company's biomarkers enable healthcare professionals, including clinicians, paramedics, and nurses, to deliver timely treatment. This advancement is expected to reduce the time to intervention, ultimately decreasing the likelihood of disabilities and fatalities associated with strokes. Upfront Diagnostics holds a portfolio of patents that protect its proprietary biomarkers, underscoring its commitment to enhancing patient care through more effective diagnostic tools.